On Friday, Denali Therapeutics Inc (NASDAQ: DNLI) opened lower -5.41% from the last session, before settling in for the closing price of $15.35. Price fluctuations for DNLI have ranged from $10.57 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -4.46% annually for the last half of the decade. Company’s average yearly earnings per share was noted -18.34% at the time writing. With a float of $125.73 million, this company’s outstanding shares have now reached $145.25 million.
In an organization with 422 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 13.46%, while institutional ownership is 92.24%. The most recent insider transaction that took place on Jul 09 ’25, was worth 7,429,230. In this transaction President and CEO of this company sold 495,282 shares at a rate of $15.00, taking the stock ownership to the 253,071 shares. Before that another transaction happened on Jul 09 ’25, when Company’s Officer proposed sale 495,282 for $14.33, making the entire transaction worth $7,097,391.
Denali Therapeutics Inc (DNLI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -18.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.54% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 9.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.67, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.31 million. That was inferior than the volume of 1.36 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.00%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 32.27%, which indicates a significant decrease from 56.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.67 in the past 14 days, which was lower than the 0.94 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.39, while its 200-day Moving Average is $19.78. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $15.12. Second resistance stands at $15.72. The third major resistance level sits at $16.09. If the price goes on to break the first support level at $14.15, it is likely to go to the next support level at $13.78. The third support level lies at $13.18 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 145,276K shares outstanding in the company with a market cap of 2.11 billion. Presently, the company’s annual sales total 0 K according to its annual income of -422,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -132,970 K.
